|
Ther-Rx products benefit from the most advanced drug-delivery technologies — technologies
that help medicines stay in place, taste better, and release themselves at a variety
of controlled rates. |
|
|
|
|
Advanced drug-delivery technologies have become the hallmark of our parent company,
KV Pharmaceutical. KV is a fully integrated specialty pharmaceutical company that
develops, manufacturers, acquires, licenses, and markets technologically distinguished
products. |
One of the unique proprietary KV technologies utilized currently at Ther-Rx Corporation is Site Release®.
KV’s Site Release® drug delivery system provides a creative, unique approach to drug delivery, combining bioadhesion to wet living tissues with controlled release of the drug agent. Products incorporating Site Release® technology are designed to adhere to wet living tissues, yet are minimally affected by the presence of moisture.
Site Release® is currently commercialized in two Ther-Rx Corporation products, Gynazole-1®
and Clindesse®, thus providing one-dose-to-treat products, with a potential to improve patient compliance, while also allowing anytime dosing with minimized leakage. Site Release® butoconazole nitrate 2% vaginal cream, used in Gyanazole-1® and clindamycin phosphate 2% vaginal cream used in Clindesse® have both received FDA approval.
|
|
|
Learn more about
KV Pharmaceutical Company |
|
|
|